Skip to main content

Table 1 Patient characteristics

From: Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making

Characteristics Total (n = 84) Surgery (n = 55) Radiotherapy (n = 29) P-value
Sex     0.406
 -Male (%) 44 (52) 27 (49) 17 (59)  
 -Female (%) 40 (48) 28 (51) 12 (41)  
Age, median (range) 68 (50–87) 65 (50–81) 73 (52–87) 0.001
Education level (%):     0.875
 -Primary education 12 (14) 8 (15) 4 (14)  
 -Secondary education 21 (55) 29 (53) 17 (59)  
 -Higher education 46 (27) 15 (27) 8 (27)  
 -Other 3 (4) 3 (5)  
Smoking habits     
 -Nonsmoker (%) 3 (4) 2 (4) 1 (3) 0.588
 -Current or former smoker (%) 60 (71) 38 (69) 22 (76)  
 -Unknown, n (%) 21 (25) 15 (27) 6 (21)  
FEV1% mean ± SDa 80 (24) 87 (20) 67 (26) 0.001
 -Unknown, n (%) 3 (4) 2 (4) 1 (3)  
DLCO (%) mean ± SDb 76 (24) 83 (22) 61 (22) <0.001
COPD (%)c     0.001
 -No COPD 38 (45) 31 (56) 7 (24)  
 -GOLD I 17 (20) 10 (18) 7 (24)  
 -GOLD II 19 (23) 13 (24) 6 (21)  
 -GOLD III 8 (10) 1 (2) 7 (24)  
 -GOLD IV 2 (2) 2 (7)  
Charlson comorbidity index (%)     0.026
 - ≤ 1 47 (56) 33 (60) 14 (48)  
 -2–3 26 (31) 17 (31) 9 (32)  
 -4 6 (7) 3 (5) 3 (10)  
 - ≥ 5 5 (6) 2 (4) 3 (10)  
Clinical stage (%)     0.001
 -IA 47 (56) 22 (40) 25 (86)  
 -IB 14 (17) 12 (22) 2 (7)  
 -IIA 17 (20) 15 (27) 2 (7)  
 -IIB 6 (7) 6 (11)   
Pathological stage (%)     
 -IA 17 (31) 17 (31)  
 -IB 18 (33) 18 (33)  
 -IIA 9 (16) 9 (16)  
 -IIB 7 (13) 7 (13)  
 -IIIA/B 4 (7) 4 (7)  
Histology (%)     0.262
 -Squamous cell carcinoma 18 (21) 14 (26) 4 (14)  
 -Adenocarcinoma 21 (25) 15 (27) 6 (21)  
 -Large cell carcinoma 8 (10) 6 (11) 2 (7)  
 -NSCLC 37 (44) 20 (36) 17 (58)  
Clinical tumor diameter (mm), median (range) 25 (7–130) 29 (7–130) 22 (9–41) <0.001
 -Unknown, n (%) 11 (5)
Pathological tumor diameter (mm), median (range) 28 (1–90) 28 (1–90)  
  1. aFEV1%: Forced expiratory volume in 1 s expressed as a percent of predicted
  2. bDiffusion capacity of the lung for carbon monoxide
  3. cCOPD: chronic obstructive pulmonary disease